[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:11][C:12]2[C:13]3[N:29]=[CH:28][S:27][C:14]=3[N:15]=[C:16]([N:18]3[CH2:23][CH2:22][CH2:21][CH:20]([C:24]([OH:26])=O)[CH2:19]3)[N:17]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10].[N:30]1[CH:35]=[CH:34][C:33]([CH2:36][CH2:37][NH2:38])=[CH:32][CH:31]=1.C(Cl)CCl.CN1C=CN=C1>C(Cl)Cl>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:11][C:12]2[C:13]3[N:29]=[CH:28][S:27][C:14]=3[N:15]=[C:16]([N:18]3[CH2:23][CH2:22][CH2:21][CH:20]([C:24]([NH:38][CH2:37][CH2:36][C:33]4[CH:34]=[CH:35][N:30]=[CH:31][CH:32]=4)=[O:26])[CH2:19]3)[N:17]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10]The mixture of 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-3-carboxylic acid (50 mg, 0.12 mmol), 2-(pyridin-4-yl)ethanamine (50 mg, 0.41 mmol), EDC (50 mg, 0.26 mmol) and 1-methyl-1H-imidazole (50 mg, 0.61 mmol) in 25 mL of DCM was stirred at room temperature overnight. Excess of DCM was removed under reduced pressure and the residue was purified by silica gel chromatography, eluting with petroleum ether and ethyl acetate (3:1) to give 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(pyridin-4-yl)ethyl)piperidine-3-carboxamide (25 mg, 39%) as a yellow sold. 1H NMR (300 MHz, DMSO): δ 9.64 (s, 1H), 8.85 (s, 1H), 8.46-8.44 (m, 2H), 8.02-8.01 (m, 1H), 7.71-7.69 (m, 1H), 7.33-7.21 (m, 3H), 6.92 (d, 1H, J=9.0 Hz), 4.64-4.63 (m, 2H), 3.75 (s, 3H), 3.73 (s, 3H), 3.35-3.30 (m, 2H), 2.98-2.91 (m, 2H), 2.77-2.75 (m, 2H), 2.51 (brs, 1H), 1.82-1.42 (m, 4H). LC-MS: 520 [M+H]+, 260 [M/2+H]+, 518 [M−H]−, tR=1.29 min. HPLC: 97.55% at 214 nm, 97.72% at 254 nm, tR=3.51 min.